Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population by Rodríguez‑Rubio, Enrique et al.
Rodríguez‑Rubio et al. Orphanet J Rare Dis          (2021) 16:104  
https://doi.org/10.1186/s13023‑021‑01729‑0
RESEARCH
Phenotypic characterization of X‑linked 
hypophosphatemia in pediatric Spanish 
population
Enrique Rodríguez‑Rubio1* , Helena Gil‑Peña2, Sara Chocron3, Leire Madariaga4, Francisco de la Cerda‑Ojeda5, 
Marta Fernández‑Fernández6, Carmen de Lucas‑Collantes7, Marta Gil8, María Isabel Luis‑Yanes9, 
Inés Vergara10, Juan David González‑Rodríguez11, Susana Ferrando12, Montserrat Antón‑Gamero13, 
Marta Carrasco Hidalgo‑Barquero14, Angustias Fernández‑Escribano15, Mº Ángeles Fernández‑Maseda16, 
Laura Espinosa17, Aniana Oliet18, Antonio Vicente19, Gema Ariceta3 and Fernando Santos1,2 on behalf of 
RenalTubeGroup 
Abstract 
Background: X‑linked hypophosphatemia (XLH) is a hereditary rare disease caused by loss‑of‑function mutations 
in PHEX gene leading tohypophosphatemia and high renal loss of phosphate. Rickets and growth retardation are the 
major manifestations of XLH in children, but there is a broad phenotypic variability. Few publications have reported 
large series of patients. Current data on the clinical spectrum of the disease, the correlation with the underlying gene 
mutations, and the long‑term outcome of patients on conventional treatment are needed, particularly because of the 
recent availability of new specific medications to treat XLH.
Results: The RenalTube database was used to retrospectively analyze 48 Spanish patients (15 men) from 39 different 
families, ranging from 3 months to 8 years and 2 months of age at the time of diagnosis (median age of 2.0 years), 
and with XLH confirmed by genetic analysis. Bone deformities, radiological signs of active rickets and growth retarda‑
tion were the most common findings at diagnosis. Mean (± SEM) height was − 1.89 ± 0.19 SDS and 55% (22/40) of 
patients had height SDS below—2. All cases had hypophosphatemia, serum phosphate being − 2.81 ± 0.11 SDS. 
Clinical manifestations and severity of the disease were similar in both genders. No genotype—phenotype correla‑
tion was found. Conventional treatment did not attenuate growth retardation after a median follow up of 7.42 years 
(IQR = 11.26; n = 26 patients) and failed to normalize serum concentrations of phosphate. Eleven patients had mild 
hyperparathyroidism and 8 patients nephrocalcinosis.
Conclusions: This study shows that growth retardation and rickets were the most prevalent clinical manifestations at 
diagnosis in a large series of Spanish pediatric patients with XLH confirmed by mutations in the PHEX gene. Traditional 
treatment with phosphate and vitamin D supplements did not improve height or corrected hypophosphatemia and 
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Background
X-linked hypophosphatemic rickets (XLH) (OMIM 
307800) (ORPHA 89936) is the most common hereditary 
rickets [1–5] with an estimated prevalence of 1:20,000 [6, 
7]. It follows an X-linked dominant transmission [8]. The 
disease is caused by a defective function of PHEX gene 
[1, 9–13], leading to elevated circulating concentrations 
of fibroblast growth factor 23 (FGF23) [14], relatively low 
levels of 1,25 dihydroxyvitamin d [1,25(OH)2D], hyper-
phosphaturia secondary to decreased proximal tubular 
reabsorption of phosphate and hypophosphatemia [8, 10, 
15]. Classical, conventional treatment of XLH is based 
on the administration of phosphate supplements and 
1-alpha hydroxylated derivates of vitamin D [16]. The 
wider availability of genetic studies and the recent devel-
opment of an anti-FGF23 antibody, burosumab, as novel 
and promising therapy [10, 17] have resulted in a growing 
current interest for XLH.
We here report the clinical manifestations at diag-
nosis and follow-up of a large series of Spanish patients 
included in the online database RenalTube [18]. This 
study is justified at least by the following reasons: (1) 
XLH is a rare disease and few publications provide data 
on large series of patients; (2) XLH has a broad pheno-
typic variability and additional information is required 
to better characterize the clinical spectrum of the disease 
and to explain why the number of cases diagnosed usu-
ally does not correspond to the estimated prevalence of 
the disease; (3) It is important to share data of patients 
with genetically confirmed XLH in order to facilitate the 
finding of a potential phenotype—genotype correlation 
and to have current data that can be compared for the 
assessment of the new therapies.
Results
Forty-eight patients included in the RenalTube database 
with the diagnosis of XLH confirmed by defect-of-func-
tion variants found in the PHEX gene were analyzed. 
All variants had been identified as pathogenic. Sixteen 
patients (33%) had variants with strong evidence of 
pathogenicity (nonsense, frameshift, deletions) while 
the other 32 (67%) harbored variants with very strong 
evidence of pathogenicity (SNPs). Demographic and 
genetic data from patients are shown in Table 1. Patients 
were from 39 families and were being followed in pedi-
atric nephrology units of 17 Spanish hospitals (Fig.  1). 
Fifteen patients were males and 33 females. Median age 
at diagnosis was 2.0 (IQR 2.6) years and the age ranged 
from 3 months to 8 years 2 months.
Presenting manifestations are shown in Table  2 for 
each patient. Bone deformities and radiological signs of 
active rickets were the most frequent findings leading to 
diagnosis. Ten patients were diagnosed because of family 
screening. Age at diagnosis of these patients was no dif-
ferent from that of the rest of the series as it ranged from 
0.5 to 8 years with a median age of 1.04 years.
Twenty-two out of40 patients (55%) in whom the height 
was registered presented growth retardation (height ≤ 2 
SDS). Patients’ height (X ± SEM) was − 1.89 ± 0.19 SDS 
(n = 40) (Fig. 2). In 87% (35/40) the height was below the 
50th percentile. Weight was − 0.88 ± 0.14 SDS (n = 41) 
and body mass index 0.2 ± 0.15 SDS (n = 40).
Biochemical findings at diagnosis are shown in 
Table  3. Mean values (± SEM) of available data were 
serum phosphate 2.7 ± 0.1  mg/dl; − 2.81 ± 0.11 SDS, 
(n = 41), alkaline phosphatase (892 ± 84 mU/ml) (n = 39), 
1,25(OH)2D62 ± 7  pg/ml (n = 34), parathyroid hormone 
(PTH)70 ± 7 pg/ml (n = 33), and tubular phosphate reab-
sorption (TPR) 69 ± 4% (n = 26).
No differences were found between males and females 
for clinical manifestations, growth impairment or bio-
chemical data at diagnosis. Likewise, no genotype–phe-
notype correlation was found. Actually, even patients 
within the same family presented different severity of 
clinical and biochemical manifestations.
Growth and biochemical variables of 26 patients after 
a median follow uptime of 7.42  years (IQR = 11.26) are 
shown in Table  4, Figs.  3 and 4. Anthropometric data 
were − 1.94 ± 0.16 SDS for height (n = 24), − 0.82 ± 0.10 
SDS for weight (n = 22) and 0.14 ± 0.19 SDS for BMI 
(n = 22). Comparison of data from patients with infor-
mation both at diagnosis and last follow-up showed 
mean variations of 0.13 ± 0.23 SDS for height (p > 0.05) 
(n = 20), 0.35 ± 0.14 SDS for weight (p = 0.02) (n = 20) 
and 0.13 ± 0.20 SDS for BMI (p > 0.05) (n = 20).
Mean SDS for serum phosphate was − 2.72 ± 0.20 
(n = 25). Alkaline phosphatases, 1,25 (OH)2D and PTH 
levels were 525 ± 82  mU/ml (n = 14), 53 ± 7  pg/ml 
(n = 15) and 68 ± 8  pg/ml (n = 26) respectively. Mean 
tubular phosphate reabsorption was 65 ± 3% (n = 22). 
Comparison between diagnosis and last follow-up data 
revealed a variation of 0.20 ± 0.28 SDS for serum phos-
phate (p > 0.05) (n = 20), 5 ± 7  pg/ml for 1,25 (OH)2D 
(p > 0.05) (n = 10), 0 ± 11  pg/ml for PTH (p > 0.05) 
was associated with a risk of hyperparathyroidism and nephrocalcinosis. The severity of the disease was similar in 
males and females.
Keywords: XLH, Inherited hypophosphatemia, Growth retardation, Bone deformities, Rickets
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Table 1 Demographic and genetic data of 48 patients belonging to 39 families (Roman number indicates family)
F: female, M: male
P: pathogenic
Patient Relationship Sex cDNA mutation Protein mutation Variant type
I.1 Index F c.758_759delTT p.F26Cfs P (PVS1)
I.2 Sister F c.758_759delTT p.F26Cfs P (PVS1)
II.1 Index F c.2223_2224delAC p.A514Afs516X P (PVS1)
III.1 Index F c.1578_1579delAA p.K299Nfs304X P (PVS1)
IV.1 Index M c.893A>T p.N71I P (PS1)
IV.2 Brother M c.893A>T p.N71I P (PS1)
V.1 Index F c.2633G>C p.R651P P (PS1)
VI.1 Index F c.1885C>T p.Q402X P (PVS1)
VII.1 Index M c.?‑2664dup2949‑? Splice region variant P (PVS1)
VII.2 Brother M c.?‑2664dup2949‑? Splice region variant P (PVS1)
VII.3 Daughter F c.?‑2664dup2949‑? Splice region variant P (PVS1)
VII.4 Daughter F c.?‑2664dup2949‑? Splice region variant P (PVS1)
VIII.1 Index F c.886insT p.K69X P (PVS1)
IX.1 Index F c.2048G>A p.W456X P (PVS1)
X.1 Index F g.22099152G>T Splice region variant P (PVS1)
XI.1 Index M c.2648_?del p.A656_?del P (PVS1)
XII.1 Index F c.2327_?del p.R549_?del P (PVS1)
XIII.1 Index F g.22168393_delA Splice region variant P (PVS1)
XIV.1 Index F c.1552C>T p.R291X P (PVS1)
XV.1 Index F g.22190503G>A Splice region variant P (PVS1)
XVI.1 Index F c.889_893delGTAAA p.V70Sfs77X P (PVS1)
XVII.1 Index F c.2086_?del p.A469_?del P (PVS1)
XVIII.1 Index F c.1180T>C p.W167R P (PS1)
XIX.1 Index F c.2282C>T p.P534L P (PS1)
XX.1 Index F c.2416G>A p.G579R P (PS1)
XXI.1 Index F c.2920C>T p.R747X P (PVS1)
XXII.1 Index F c.2920C>T p.R747X P (PVS1)
XXIII.1 Index M c.1152delA p.L157Lfs220X P (PVS1)
XXIV.1 Index F c.1572C>A,c.1580_1582delTGA p.Y297X P (PVS1)
XXV.1 Index F g.22076478A>T Splice region variant P (PVS1)
XXVI.1 Index F g.22190507G>A Splice region variant P (PVS1)
XXVII.1 Index F c.889_893delGTAAA p.V70Sfs77X P (PVS1)
XXVII.2 Father M c.889_893delGTAAA p.V70Sfs77X P (PVS1)
XXVIII.1 Index M c.2879G>T p.C733F P (PS1)
XXVIII.2 Sister F c.2879G>T p.C733F P (PS1)
XXIX.1 Index F c.2642T>C p.F654S P (PS1)
XXX.1 Index M c.2387T>G p.L569R P (PS1)
XXX.2 Mother F c.2387T>G p.L569R P (PS1)
XXXI.1 Index F c.2085G>C p.K468N P (PS1)
XXXII.1 Index M c.2282C>T p.P534L P (PS1)
XXXIII.1 Index M g.22033125T>G Splice region variant P (PVS1)
XXXIV.1 Index M c.2380C>T p.R567X P (PVS1)
XXXV.1 Index M c.2005G>T p.V442P P (PS1)
XXXV.2 Mother F c.2005G>T p.V442P P (PS1)
XXXVI.1 Index F c.2416G>A G579R P (PS1)
XXXVII.1 Index M g.22099152G>A Splice region variant P (PVS1)
XXXVIII.1 Index F c.2617delG p.D646Ifs P (PVS1)
XXXIX.1 Index M c.1363_1364delTC p.S228Pfs236X P (PVS1)
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(n = 16) and − 7 ± 8 for tubular phosphate reabsorption 
(p > 0.05) (n = 11).
Eight out of 24 patients with renal ultrasounds at last 
follow-up presented nephrocalcinosis (Table 5).
Discussion
This study provides a current description of the phe-
notypic characteristics of a large cohort of Caucasian 
pediatric patients with XLH genetically confirmed. The 
sample is a broad representation of the Spanish chil-
dren with XLH, coming from several hospitals scattered 
through the country and provides data at diagnosis and 
after a median follow-up of 7.42  years. The study con-
firms that growth retardation, bone deformities and 
active lesions of rickets are the main presenting manifes-
tations of the disease, within a wide spectrum of symp-
toms. No significant differences were found between 
males and females as for the severity of the disease. It is 
of interest that a broad spectrum of PHEX gene variants, 
all of them already described as pathogenic, was found 
and no mutation was specifically prevalent in Spanish 
population. All variants were classified as pathogenic 
according to the American College of Medical Genetics 
and Genomics consensus [19]. There was a high pheno-
typical variability even among family members harbor-
ing the same mutations, suggesting that other genes and 
environmental factors may affect the severity of XLH, as 
reported by other authors [20, 21].
In addition, the study shows that conventional treat-
ment with phosphate supplements and vitamin D 
metabolites does not lead to persistent correction of 
hypophosphatemia or reduction of renal wasting of 
phosphate and does not modify the circulating levels 
of calcitriol. Unfortunately, this study does not provide 
information on circulating FGF23 levels, given its ret-
rospective design. At the last follow-up visit, 11 out of 
25 patients had serum PTH values mildly elevated. In 
XLH, development of hyperparathyroidism is thought 
to be related with the pharmacological administration 
of phosphate [22]. Eight patients developed nephrocalci-
nosis during the follow-up period, a finding linked to the 
PVS1: very strong evidence of pathogenicity according to reference 19
PS1: strong evidence of pathogenicity according to reference 19
Table 1 (continued)
Fig. 1 Geographical distribution of the Spanish hospitals participating in the study
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Table 2 Clinical manifestations at diagnosis
Patient Age at diagnosis Bone deformities Active rickets Longitudinal growth retardation 
(≤ 2 SDS)
Dental problems
I.1 3 m No – No –
I.2 1 y Yes – Yes –
II.1 1 y 5 m Yes Yes Yes No
III.1 1 y 6 m – Yes Yes Yes
IV.1 1 y 4 m No No Yes Yes
IV.2 4 y No No No No
V.1 5 y Yes Yes Yes No
VI.1 2 y Yes No No No
VII.1 8 y – – – –
VII.2 2 y – Yes – No
VII.3 11 m – Yes Yes No
VII.4 1 y – – Yes –
VIII.1 4 y Yes Yes No No
IX.1 5 y Yes Yes No No
X.1 5 y Yes Yes Yes No
XI.1 2 y 3 m Yes Yes Yes No
XII.1 2 y Yes Yes – –
XIII.1 5 y – Yes – –
XIV.1 9 m Yes Yes No No
XV.1 1 y 1 m Yes Yes Yes –
XVI.1 4 y Yes – Yes No
XVII.1 5 y – – Yes –
XVIII.1 2 y Yes Yes Yes No
XIX.1 7 m Yes Yes – No
XX.1 2 y 1 m Yes – Yes –
XXI.1 4 y 5 m Yes Yes No No
XXII.1 4 y Yes Yes Yes No
XIII.1 2 y Yes Yes No No
XXIV.1 3 y Yes – No –
XXV.1 1 y 6 Yes Yes No No
XXVI.1 4 y Yes Yes Yes No
XXVII.1 6 m Yes Yes No No
XXVII.2 8 y – Yes – No
XXVIII.1 1 y 6 m Yes – No –
XXVIII.2 6 m Yes Yes No No
XXIX.1 1 y 9 m Yes Yes Yes No
XXX.1 1 y 1 m Yes Yes Yes –
XXX.2 1 y 6 m – Yes – No
XXXI.1 8 y2 m Yes Yes Yes No
XXXII.1 1 y 6 m Yes Yes No No
XXXIII.1 5 y – – Yes –
XXXIV.1 2 y 2 m Yes Yes No No
XXXV.1 7 m Yes Yes No –
XXXV.2 2 y 6 m Yes Yes Yes –
XXXVI.1 6 m Yes Yes No No
XXXVII.1 1 y 9 m Yes Yes Yes Yes
XXXVIII.1 1 y 6 m Yes Yes No No
XXXIX.1 2 y 2 m Yes Yes – No
Percentage of patients P/A/U P/A/U P/A/U P/A/U
73/6/21 73/6/21 46/38/17 6/63/31
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administration of phosphate and vitamin D that usually 
does not result in subsequent clinical complications [16].
Though conventional treatment has been described 
to heal active signs of rickets and may improve bone 
deformities [23], this study confirms that it does not lead 
to catch-up growth. Mean height Z score of the group of 
patients remained low, − 1.89 at diagnosis versus − 1.94 
at the last visit, although Fig.  3 indicates that the indi-
vidual patients’ response varied from marked improve-
ment to worsening of growth impairment. Two patients, 
VII.3 and XV.1, transiently received growth hormone 
treatment and their heights improved + 2.19and + 0.66 
SDS, respectively. It is of note that 4 out of 16 patients 
had BMI greater than + 1.00 SDS at the last follow-up 
visit. This percentage of 25% corresponds to the normal 
distribution of reference population and it indicates that 
tendency to overweight and obesity was not found in the 
group of XLH patients here reported, unlike other series 
that have recently drawn attention to these complications 
likely related with the sedentary life and restricted mobil-
ity of these patients [11]. In this regard, a slight but signif-
icant increase in weight was found during the follow-up 
period in our series.
Our study presents methodological limitations inherent 
to the retrospective analysis and to the fact that patients’ 
information was extracted from a database in which some 
data were missing and cannot be recovered. It is also of 
note the lack of information on the degree of adherence 
to medication of each patient as well as the different 
monitoring protocols among the participating centers. 
However, it is an observational clinical study describing a 
large cohort of Spanish pediatric patients with genetically 
confirmed XLH and it provides current and interesting 
information on the clinical and biochemical features of 
the disease, at diagnosis and follow-up after conventional 
treatment. Our findings could be used as reference for 
further studies using burosumab treatment.
Conclusions
This study confirms that growth retardation and rickets 
were the most prevalent clinical manifestations at diag-
nosis in a large series of Spanish pediatric patients with 
XLH confirmed by identification of pathogenic variants 
in the PHEX gene. Traditional treatment with phosphate 
supplements and calcitriol did not improve height or cor-
rected hypophosphatemia and was associated with a risk 
Table 2 (continued)
m: month, y: year
SDS: standard deviation score. Dash: information in this field was missing from the database
P/A/U: present/absent/unreported
Fig. 2 Height at diagnosis (n = 40). Black line: 0 SD; red line: − 2 SD
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Table 3 Biochemical manifestations at diagnosis




Serum intact PTH (pg/ml) TPR (%)
mg/dl SDS
I.1 3.4 − 2.21 1230 87 – –
I.2 3.8 − 1.05 1916 76 – –
II.1 2.6 − 2.68 695 57 81 79
III.1 2.1 − 3.36 1646 16 68 32
IV.1 2.8 − 2.41 378 73 29 78
IV.2 3.0 − 2.44 232 40 43 82
V.1 2.1 − 3.99 1513 147 78 85
VI.1 2.6 − 2.68 525 33 64 78
VII.1 – – – – – –
VII.2 2.4 − 2.95 516 – – –
VII.3 – – 991 28 30 –
VII.4 – – – – – –
VIII.1 3.1 − 2.27 598 55 39 38
IX.1 3.0 − 2.44 1824 47 59 67
X.1 2.9 − 2.61 639 33 136 74
XI.1 2.3 − 3.09 – – 58 –
XII.1 2.7 − 2.54 – – 48 –
XIII.1 – – – – – –
XIV.1 3.3 − 2.34 892 64 65 75
XV.1 2.0 − 3.49 704 20 – 39
XVI.1 2.4 − 3.47 571 108 71 26
XVII.1 2.5 − 3.30 – 28 30 –
XVIII.1 2.3 − 3.09 1864 31 64 73
XIX.1 – – – – – –
XX.1 2.9 − 2.27 446 88 116 93
XXI.1 3.1 − 2.27 470 56 49 86
XXII.1 2.8 − 2.78 697 74 32 76
XXIII.1 2.1 − 3.36 733 – 68 82
XXIV.1 2.2 − 3.22 514 61 78 58
XXV.1 2.9 − 2.27 1940 40 57 58
XXVI.1 2.3 − 3.64 423 – – 82
XXVII.1 2.9 − 2.86 432 31 23 –
XXVII.2 – – – – – –
XXVIII.1 3.0 − 2.14 236 78 54 –
XXVIII.2 3.3 − 2.34 426 171 57 90
XXIX.1 1.8 − 3.77 1555 – – –
XXX.1 3.1 − 2.00 829 183 101 88
XXX.2 2.2 − 3.22 158 25 – –
XXXI.1 – – – – – –
XXXII.1 2.8 − 2.41 692 41 111 –
XXXIII.1 2.1 − 3.99 – – 76 54
XXXIV.1 2.3 − 3.09 856 64 101 46
XXXV.1 3.5 − 2.08 916 – 227 82
XXXV.2 2.2 − 3.22 1620 – – 70
XXXVI.1 2.8 − 2.41 1093 65 66 –
XXXVII.1 2.4 − 2.95 1527 46 94 –
XXXVIII.1 2.4 − 2.95 856 40 58 –
XXXIX.1 3.0 − 2.14 759 51 43 –
1,25(OH)2D: 1,25 dihydroxyvitamin D. PTH: Parathyroid hormone
TPR: tubular phosphate reabsorption. Dash: information in this field was missing from the database
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Table 4 Biochemical manifestations at last follow up




Serum intact PTH 
(pg/ml)
TPR (%)
mg/dl SD (Z score)
I.1 7 y 2 m 2.9 − 2.07 787 – 30 72
I.2 10 y 1 m 2.7 − 2.90 1035 – 35 50
II.1 1 y 1 m 3.8 − 1.05 – – 34 70
III.1 – – – – – – –
IV.1 7 y 6 m 3.0 − 1.91 231 78 32 60
IV.2 7 y 6 m 2.6 − 3.06 266 73 44 48
V.1 – – – – – – –
VI.1 – – – – – – –
VII.1 – – – – – – –
VII.2 – – – – – – –
VII.3 8 y 4 m 1.9 − 3.69 – – 77 42
VII.4 8 y 3 m 1.8 − 3.85 665 – 108 73
VIII.1 2 y 7 m 2.4 − 3.47 868 15 84 81
IX.1 – – – – – – –
X.1 7 y 5 m 3.0 − 2.41 962 50 93 85
XI.1 5 y 11 m 2.8 − 2.78 632 45 49 42
XII.1 11 y 5 m 2.8 − 2.23 636 – 112 86
XIII.1 17 y 6 m 1.7 − 4.22 – 29 86 64
XIV.1 2 y 1 m 2.8 − 2.41 – 96 20 70
XV.1 25 y 5 m 2.0 − 3.55 – 20 75 45
XVI.1 – – – – – – –
XVII.1 18 y 8 m 1.7 − 4.22 120 32 99 42
XVIII.1 – – – – – – –
XIX.1 26 y 2 m 2.4 − 2.66 – – 200 –
XX.1 1 y 9 m 3.3 − 1.73 312 72 53 45
XXI.1 3 y 5 m 2.6 − 2.56 348 43 26 53
XXII.1 – – – – – – –
XXIII.1 2 y 10 m 3.0 − 2.44 – 29 28 –
XXIV.1 – – – – – – –
XXV.1 16 y 1.9 − 3.77 – – 37 –
XXVI.1 2 y 4 m 2.8 − 2.78 240 86 25 70
XXVII.1 1 y 10 m 2.8 − 2.41 – 58 49 76
XXVII.2 37 y 4 m 2.3 − 2.88 – – 117 80
XXVIII.1 – – – – – – –
XXVIII.2 – – – – – – –
XXIX.1 1 y 10 m 4.8 0.31 244 68 73 89
XXX.1 – – – – – – –
XXX.2 – – – – – – –
XXXI.1 – – – – – – –
XXXII.1 – – – – – – –
XXXIII.1 4 y 2.1 − 3.36 – – 114 76
XXXIV.1 – – – – – – –
XXXV.1 – – – – – – –
XXXV.2 – – – – – – –
XXXVI.1 – – – – – – –
XXXVII.1 – – – – – – –
XXXVIII.1 – – – – – – –
XXXIX.1 – – – – – – –
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Table 4 (continued)
1,25(OH)2D: 1,25 dihydroxyvitamin D
m: month, y: year
PTH: parathyroid hormone
TPR: tubular phosphate reabsorption. Dash: information in this field was missing from the database
Serum Phosphate (Z Score) Alkaline Phosphatases (mU/ml) TPR (%)







Last Follow-Up Last Follow-Up Last Follow-Up





Fig. 3 Biochemical and growth data at diagnosis and last follow‑up. TPR: tubular phosphate reabsorption. BMI: Body Mass Index. Mean values are 
connected by red dots line. Vertical bars represent ± SEM
Fig. 4 Height at last follow‑up (n = 24). Black line: 0 SD; red line: − 2 SD
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of hyperparathyroidism and nephrocalcinosis. The sever-
ity of the disease was similar in males and females and no 
phenotype-genotype association was found.
Patients and methods
The RenalTube database including 48 patients, 15 males 
and 33 females, with the diagnosis of XLH confirmed by 
defect-of-function mutations found in the PHEX gene 
was retrospectively reviewed to obtain demographic 
information and clinical and biochemical manifestations 
at diagnosis and at the last annual follow-up. Genetic 
information was confirmed and formatted according to 
Genome Reference Consortium Human Build 38 patch 
release 13 (GRCh38.p13) [24]. Variants were analyzed 
in silico and classified according to recommendations 
from the consensus of the American College of Medical 
Genetics and Genomics and the Association for Molec-
ular Pathology [19] as pathogenic, likely pathogenic, 
benign or likely benign. Results for the age are presented 
as median and interquartile range (IQR). Other variables 
are presented for the group as mean (X) ± standard error 
of the mean (SEM). Z score (SDS) of anthropometric val-
ues was calculated using Spanish age and sex-matched 
reference values [25]. Patients with height ≤ 2 SDS 
were considered to have longitudinal growth retarda-
tion according to World Health Organization standards 
[26]. Reference values for biochemical parameters were 
obtained from the laboratory of the Hospital Universi-
tario Central de Asturias (HUCA) [27].
All patients received treatment with phosphate sup-
plementation (dose range of phosphorus element: 
27–90  mg/kg/day at last follow-up) and vitamin D 
metabolites (dose range: 0.25–1.5  µg/day at last follow-
up), according to the criteria and indications given by 
their physicians (Table 5). Two patients (VII.3 and XV.1) 
received growth hormone treatment. None of them 
received burosumab treatment.
Information in RenalTube database was downloaded 
and formatted to an Excel database. All fields but reasons 
for consultation and genetic information were multi-
choice or numeric format.
Chi squared test was used to analyze differences 
between sex for binary (Yes/No) fields (growth retarda-
tion, bone deformities). F-test was used to assess variance 
equality between sex for anthropometric and biochemi-
cal values. T-test was used to analyze differences between 
sex for anthropometric and biochemical values. Paired 
Table 5 Treatment and clinical data at last follow‑up
Patient Phosphorus element 
dose (mg/kg/day)
Vitamin D dose 
(µg/day)
Nephrocalcinosis
I.1 38a 0.50c No
I.2 40a 0.50c No
II.1 86a 1.20d Yes
III.1 – – –
IV.1 83a 0.60d No
IV.2 62a 1.00d No
V.1 – – –
VI.1 – – –
VII.1 – – No
VII.2 – – –
VII.3 55b 0.50c Yes
VII.4 52b 0.50c Yes
VIII.1 90a 1.50d Yes
IX.1 – – –
X.1 40a 0.25d No
XI.1 83a 0.50c No
XII.1 44b 0.29d No
XIII.1 41b 0.25c Yes
XIV.1 52a 1.20d –
XV.1 41b 1.00c No
XVI.1 – – –
XVII.1 45b 0.25c Yes
XVIII.1 – – –
XIX.1 27b 0.50c Yes
XX.1 32a 0.50c No
XXI.1 63a 1.50d No
XXII.1 – – –
XXIII.1 65a 1.10d No
XXIV.1 – – –
XXV.1 38a 1.40c –
XXVI.1 58b 0.25c No
XXVII.1 48b 0.60d No
XXVII.2 – – –
XXVIII.1 – – –
XXVIII.2 – – –
XXIX.1 – 0.10d No
XXX.1 – – –
XXX.2 – – Yes
XXXI.1 – – –
XXXII.1 – – –
XXXIII.1 49b 0.75c No
XXXIV.1 – – –
XXXV.1 – – –
XXXV.2 – – –
XXXVI.1 – – –
XXXVII.1 – – –
XXXVIII.1 – – –
XXXIX.1 – – –
Table 5 (continued)
a Phosphate was administered as a solution
b Phosphate was administered as tablets
c Corresponds to 1,25 dihydroxy vitamin D
d Corresponds to 1 hydroxy vitamin D
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T-test for means was used to analyze differences between 
diagnosis and last follow-up for anthropometric and bio-
chemical values. T-test for unequal variances was used to 
compare age at diagnosis for patients with and without 
family history of the disease.
Phenotype—genotype correlation was assessed by iso-
lating the most severe phenotypes (lowest serum concen-
trations, most severe growth retardation, highest levels of 
alkaline phosphatases) and comparing genetic mutations 
in these patients looking for big deletions, SNPs with 
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